Charissa N L K Kahue, MD | |
3288 Moanalua Rd, Honolulu, HI 96819-1469 | |
(808) 432-0000 | |
Not Available |
Full Name | Charissa N L K Kahue |
---|---|
Gender | Female |
Speciality | Otolaryngology |
Experience | 10 Years |
Location | 3288 Moanalua Rd, Honolulu, Hawaii |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265852305 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 04-42261 (Kansas) | Secondary |
207Y00000X | Otolaryngology | 61574 (Tennessee) | Secondary |
207Y00000X | Otolaryngology | MD-22258 (Hawaii) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kaiser Foundation Hospital | Honolulu, HI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hawaii Permanente Medical Group Inc | 7618880667 | 541 |
News Archive
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
Researchers working in a research project within the Academy of Finland's Research Programme on Substance Use and Addictions have been developing a targeted drug that could aid in smoking reduction therapy. The new drug slows down the metabolism of nicotine, which would help smokers to cut down their smoking.
A new study published in Pediatrics demonstrates the cost-saving and health care quality outcomes of the pediatric Accountable Care Organization Partners for Kids. Results of this study indicate that Partners for Kids successfully improved the value of pediatric healthcare over time through cost containment, while maintaining quality of care.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
› Verified 1 days ago
Entity Name | Hawaii Permanente Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710945969 PECOS PAC ID: 7618880667 Enrollment ID: O20031106000625 |
News Archive
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
Researchers working in a research project within the Academy of Finland's Research Programme on Substance Use and Addictions have been developing a targeted drug that could aid in smoking reduction therapy. The new drug slows down the metabolism of nicotine, which would help smokers to cut down their smoking.
A new study published in Pediatrics demonstrates the cost-saving and health care quality outcomes of the pediatric Accountable Care Organization Partners for Kids. Results of this study indicate that Partners for Kids successfully improved the value of pediatric healthcare over time through cost containment, while maintaining quality of care.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Charissa N L K Kahue, MD 3288 Moanalua Rd, Honolulu, HI 96819-1469 Ph: (808) 432-0000 | Charissa N L K Kahue, MD 3288 Moanalua Rd, Honolulu, HI 96819-1469 Ph: (808) 432-0000 |
News Archive
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
Researchers working in a research project within the Academy of Finland's Research Programme on Substance Use and Addictions have been developing a targeted drug that could aid in smoking reduction therapy. The new drug slows down the metabolism of nicotine, which would help smokers to cut down their smoking.
A new study published in Pediatrics demonstrates the cost-saving and health care quality outcomes of the pediatric Accountable Care Organization Partners for Kids. Results of this study indicate that Partners for Kids successfully improved the value of pediatric healthcare over time through cost containment, while maintaining quality of care.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
› Verified 1 days ago
Jae H. Lim, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. Eric Daniel Wirtz, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Jarrett White Road, Tripler Army Medical Center, Honolulu, HI 96859 Phone: 808-433-3181 | |
Dr. Kristi Adachi, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1380 Lusitana St Ste 502, Honolulu, HI 96813 Phone: 808-533-0711 Fax: 808-538-6763 | |
Dr. Marcelo A Obando, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. John Jung Wan Cho, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 888 S King St, Honolulu, HI 96813 Phone: 808-522-4530 Fax: 808-522-4529 | |
Dr. Patrick Joseph O'donnell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1319 Punahou St Ste 1120, Honolulu, HI 96826 Phone: 808-983-6447 Fax: 808-983-8854 |